IGMS
Closed
Igm Biosciences Inc
1.29
+0.17 (+15.18%)
Last Update: 01 Jul 2025 23:19:00
Yesterday: 1.12
Day's Range: 1.29 - 1.39
Send
sign up or login to leave a comment!
When Written:
13.96
IGM Biosciences Inc is a clinical-stage biotechnology company that develops engineered IgM antibodies for the treatment of cancer and other diseases. The company's proprietary technology platform enables the creation of IgM antibodies with enhanced efficacy, improved pharmacokinetics, and reduced immunogenicity compared to traditional IgG antibodies.
IGM Biosciences' lead product candidate, IGM-2323, is being developed for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphoma and other B-cell malignancies. The company is also developing a pipeline of other IgM antibodies for the treatment of solid tumors and autoimmune diseases.
IGM Biosciences was founded in 2010 and is headquartered in Mountain View, California. The company went public in 2019 and is listed on the NASDAQ under the ticker symbol "IGMS."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
IGM Biosciences' lead product candidate, IGM-2323, is being developed for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphoma and other B-cell malignancies. The company is also developing a pipeline of other IgM antibodies for the treatment of solid tumors and autoimmune diseases.
IGM Biosciences was founded in 2010 and is headquartered in Mountain View, California. The company went public in 2019 and is listed on the NASDAQ under the ticker symbol "IGMS."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








